Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive save search
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
Published: 2024-04-02 (Crawled : 14:30) - biospace.com/
PTPI | $0.677 1.03% 1.02% 200K
|
| Email alert
Add to watchlist
positive pharmaceuticals results study
C-Bond Systems Reports 2023 Highlights Including Record Revenue and Positive Net Income; Company to Host Conference Call on April 3rd
Published: 2024-04-02 (Crawled : 12:30) - globenewswire.com
CBNT | $0.0042 122.22% 130K
|
Manufacturing
|
| O: -11.63%
H: 7.89%
C: 7.89%
conference company revenue positive
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
Published: 2024-04-02 (Crawled : 12:30) - prnewswire.com
GNPX | $2.15 0.94% 0.93% 19K
|
Health Technology
|
| O: -5.72%
H: 7.14%
C: 1.43%
oncoprex positive system preclinical therapy
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Published: 2024-04-02 (Crawled : 11:00) - globenewswire.com
ROIV | $10.61 1.43% 1.41% 5.3M
|
Manufacturing
|
| O: 4.79%
H: 3.02%
C: -0.09%
pharma million authorization positive repurchase results study
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Published: 2024-04-02 (Crawled : 08:00) - biospace.com/
AZN | News | $70.12 2.29% 2.24% 4.8M
|
Health Technology
|
| O: -1.18%
H: 0.34%
C: -0.22%
breast her2 license cancer application negative
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
Published: 2024-04-01 (Crawled : 22:00) - globenewswire.com
OCGN | News A | $1.23 -6.82% -7.32% 7.6M
|
Health Technology
|
| O: -10.0%
H: 0.69%
C: -4.17%
ocu410 disease review positive study
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Published: 2024-04-01 (Crawled : 20:00) - globenewswire.com
GRTS | $0.7453 1.18% 1.17% 3.4M
|
Health Technology
|
| O: -48.62%
H: 5.38%
C: -7.69%
positive cancer ongoing tumor dna study
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Published: 2024-04-01 (Crawled : 19:00) - biospace.com/
CNTX | $1.32 -1.44% 14K
|
Health Technology
|
| O: 8.7%
H: 3.33%
C: -8.67%
ctim-76 application therapeutics
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
Published: 2024-04-01 (Crawled : 19:00) - biospace.com/
EQ | $1.66 3.11% 3.01% 56K
|
Health Technology
|
| O: -1.73%
H: 0.0%
C: -7.05%
lupus positive topline study
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
VTGN | $4.79 0.63% 0.63% 140K
|
Health Technology
|
| O: -2.27%
H: 0.0%
C: 0.0%
positive treatment results study
Digihost Announces 60% Month-Over-Month Increase in Cash and Crypto Position and Provides March 2024 Production Update
Published: 2024-04-01 (Crawled : 11:00) - globenewswire.com
DGHI | $1.28 -5.19% -5.47% 160K
|
n/a
|
| O: 5.76%
H: 0.0%
C: -2.72%
update
MoneyGram Expands Leadership Position in Middle East through Partnership with Fintech App barraq
Published: 2024-03-28 (Crawled : 13:30) - prnewswire.com
MGI | $10.99 0.08% 0
|
Commercial Services
| Email alert
Add to watchlist
partnership
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
Published: 2024-03-28 (Crawled : 12:30) - globenewswire.com
NXL | $1.65 15.38% 13.33% 120K
|
|
| O: 8.99%
H: 0.0%
C: 0.0%
device positive technology results study
BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis
Published: 2024-03-28 (Crawled : 12:00) - globenewswire.com
BWAY | $4.79 -1.64% -1.67% 53K
|
Health Technology
|
| O: -0.19%
H: 3.15%
C: 0.95%
positive depression results
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
Published: 2024-03-27 (Crawled : 16:00) - globenewswire.com
AGNPF | $0.0756 178.69% 4.4K
|
Health Technology
|
| O: 25.81%
H: 0.0%
C: 0.0%
acquisition pharmaceuticals research program
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
PMVP | $1.725 7.14% 6.67% 540K
|
Commercial Services
|
| O: -1.2%
H: 4.27%
C: 0.61%
tp53 first tumors pharmaceuticals global trial
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
ALGS | $0.805 7.33% 6.83% 470K
|
Health Technology
|
| O: -1.96%
H: 0.0%
C: -2.1%
alg-0550 alg-000184 positive therapeutics
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-27 (Crawled : 11:00) - globenewswire.com
ALT | $7.48 8.25% 7.62% 2.3M
|
Commercial Services
|
| O: 7.63%
H: 3.33%
C: -4.51%
year positive financial results
atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
Published: 2024-03-27 (Crawled : 11:00) - globenewswire.com
ATAI | $1.88 1.62% 1.07% 1M
|
Manufacturing
|
| O: 4.05%
H: 1.11%
C: -0.56%
bpl-003 label life positive depression treatment sciences results study
Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date March 15, 2024
Published: 2024-03-26 (Crawled : 21:00) - globenewswire.com
NDAQ | $61.22 1.44% 1.42% 2.1M
|
Finance
|
| O: 0.58%
H: 0.78%
C: 0.66%
nasdaq
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.